IQVIA cuts sales guidance as site staff shortages delay execution of deliveries

By Nick Taylor

- Last updated on GMT

© Joseph Reynolds / Getty Images
© Joseph Reynolds / Getty Images

Related tags: IQVIA, Clinical trials

IQVIA has reduced its full-year sales guidance in response to factors including bottlenecks created by staff shortages at certain sites.

Talking to investors on the company's third-quarter results conference call, IQVIA CEO Ari Bousbib set out how staffing pressures are affecting both his own business and the sites that enroll and treat patients.  

It happens to be that what we have been dealing with ... very high levels of attrition. People have a hard time going back to work. We have a harder time recruiting the skill sets that we require, plus the impact on cost of labor that all of that has. All of these factors in combination are a significant, or the single most important, operational challenge we have seen​,” said Bousbib.

Some sites that IQVIA works with to execute trials are facing similar challenges. On the third quarter call, the service provider added investigator staff shortages at certain sites to the list of macro challenges it faces.

IQVIA cited site staffing issues as a factor in its decision to reduce its full-year guidance, lowering the midpoint of the range by $100m. Bousbib set out how the issues contributed to the lower sales outlook for the year.

As we end the year, we are anticipating some minor delays in the timing of deliveries caused by this macro-disruptions and specifically by the bottlenecks that are created by staff shortages at certain sites and that are delaying the execution of our deliveries​,” said the CEO.

Bousbib, quoting talks at a clinical trial summit last month, called the investigator site staffing issues an industry-wide development. An analyst brought up the topic of site staff shortages on Thermo Fisher Scientific’s quarterly results conference call, although CEO Marc Casper focused his response on the part of the question about the effect of wage inflation on its clinical research unit PPD.

The way wage inflation works in that business is it gets passed through in the normal course pricing in the contract, so that you could have a quarter or something lag. But effectively if there is unusual wage inflation this gets passed through to the customer base, so I don’t see any particular significant challenge there​,” said Casper.

Related news

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more